Lau, George and Yu, Ming-Lung and Wong, Grace and Thompson, Alexander and Ghazinian, Hasmik and Hou, Jin-Lin and Piratvisuth, Teerha and Jia, Ji-Dong and Mizokami, Masashi and Cheng, Gregory and Chen, Guo-Feng and Liu, Zhen-Wen and Baatarkhuu, Oidov and Cheng, Ann Lii and Ng, Woon Leung and Lau, Patrick and Mok, Tony and Chang, Jer-Ming and Hamid, Saeed and Dokmeci, A. Kadir and Gani, Rino A. and Payawal, Diana A. and Chow, Pierce and Park, Joong-Won and Strasser, Simone and Mohamed, Rosmawaiti and Win, Khin Maung and Tawesak, Tanwandee and Sarin, Shiv Kumar and Omata, Masao (2021) APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatology International, 15 (5). pp. 1031-1048. ISSN 1936-0533, DOI https://doi.org/10.1007/s12072-021-10239-x.
Full text not available from this repository.Abstract
Background & Aim Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | APASL; Hepatitis B reactivation; Immunosuppressive therapy; Guideline |
| Divisions: | Universiti Malaya Medical Centre (UMMC) |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 14 Jul 2022 02:23 |
| Last Modified: | 30 Apr 2025 08:42 |
| URI: | http://eprints.um.edu.my/id/eprint/34699 |
Actions (login required)
 |
View Item |
